BACKGROUND: Benefit of treatment with the monoclonal anti-IgE-antibody omalizumab in
severe IgE-dependent asthma requires a significant reduction of serum free IgE …

Therapeutic antibodies are an important part of Biopharmaceuticals. They are highly
innovative and specific drugs. Additionally, they play a challenging role in new demands in …

Objective. Monoclonal antibodies are important in the treatment of rheumatoid arthritis (RA).
This is the first trial to monitor the effect of adalimumab dose escalation in persistently active …

The therapeutic use of antibodies has grown exponentially, providing new treatment options
for various diseases. Monitoring treatment with therapeutic antibodies is a particular …

Methods The aim of our work was to develop an in-vitro procedure for the estimation of both
the therapeutic antibody and the antigen in serum samples by use of a sandwich assay. …

It is stated that benefit of omalizumab treatment in severe IgE-dependent asthma requires
serum free IgE concentrations below 50 ng/ml. It is unclear if monitoring free serum IgE is …

The ability of omalizumab, a monoclonal anti-IgE antibody, to reduce free serum IgE levels
is dependent on dose, the patient's weight and serum total IgE level. A clinical benefit with …

Affinity parameters obtained from standard calibration curves of radioimmunoassays (RIA)
have been shown to decrease with increasing antibody concentration. A modified binding …

Results: A total of 41 subjects (21 females, mean age; 41 years, 70, 70% atopics) completed
both visits. Mean FEV1% predicted at baseline was 94, 13%(SD 17, 71). There was a …

The Revovery-ELISA (R-ELISA) resembles a combination of a Sandwich-ELISA for the
antigen and a competitive ELISA for the therapeutic antibody. The R-ELISA is a special ELISA …